Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post-Kala-Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing. [PDF]
Post‐kala‐azar dermal leishmaniasis (PKDL) involves a high macrophage burden in which the Leishmania parasites reside. Liposomal amphotericin B (LAmB) plays a key role in the treatment of PKDL. The mononuclear phagocyte system (MPS) is crucial in the distribution of liposomal drugs as well as the leishmaniasis pathophysiology.
Chu WY +12 more
europepmc +2 more sources
Visceral leishmaniasis (kala-azar) caused by L. mexicana in a patient with AIDS. [PDF]
Mitchell KL +5 more
europepmc +1 more source
Can cutaneous leishmaniasis provoke a resurgence of kala-azar in the Indian subcontinent? [PDF]
Bhattarai NR +12 more
europepmc +1 more source
Revisiting the diagnosis and treatment of Para Kala-azar Dermal Leishmaniasis in the endemic foci of Bangladesh. [PDF]
Maruf S +9 more
europepmc +1 more source
Immune-Pathological Correlates of Disease Severity in New-World Kala-Azar: The Role of Parasite Load and Cytokine Profiles. [PDF]
Sene IS +7 more
europepmc +1 more source
Evaluation of Renal Function Profile in Human Visceral Leishmaniasis (Kala-Azar) Patients: A Case of Western Tigray, Ethiopia. [PDF]
Asfaw KG, Gizaw ST, Gnanasekaran N.
europepmc +1 more source
Assessment of Knowledge, Attitudes, and Practices toward Kala-azar in an Endemic District in Bangladesh: A Cross-Sectional Survey. [PDF]
Faria S +4 more
europepmc +1 more source
Epidemiological insights and clinical management of paediatric kala-azar in Shanxi Province (2014-2023): retrospective analysis of case characteristics and therapeutic strategies. [PDF]
Zhao J, Ullah I, Fan H, Li X.
europepmc +1 more source
Visceral Leishmaniasis (Kala-Azar): A Triumph Against a Trickster Disease. [PDF]
Pasha F +4 more
europepmc +1 more source
Post-Kala-Azar Dermal Leishmaniasis. [PDF]
Sharma A, Bishnoi A, Parsad D.
europepmc +1 more source

